Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CYBERDYNE Inc. (7779.T)
Tsukuba, JP
Headquartered in Tsukuba, Japan, and founded in 2004, CYBERDYNE Inc. is dedicated to the ongoing research, development, production, sales, leasing, and maintenance of sophisticated equipment and systems, primarily for the medical and defense sectors within Japan. Their innovative product line features the Hybrid Assistive Limb (HAL), available in medical variants for lower limbs and single joints, as well as non-medical versions designed for lower limbs, single joints, and lumbar support. The company also supplies HAL peripherals, robotic cleaners, and autonomous transport robots for factories, offices, and various other indoor environments. A notable technological offering is Acoustic X, a high-speed light pulse LED array that facilitates real-time photoacoustic imaging. Complementing their hardware, CYBERDYNE provides specialized treatments and programs such as Cybernics Treatment, which utilizes HAL to restore or enhance function for individuals suffering from conditions like spinal cord injuries, strokes, and neuromuscular disorders. They additionally offer HAL FIT and Neuro HALFIT to improve brain-nerve-musculoskeletal and general physical functions, respectively, and MTX Neuro HAL Plus to optimize brain-nerve performance in athletes. Furthermore, the company extends its expertise to critical areas including disaster rescue operations, heavy industrial labor assistance, and contributions to the entertainment industry.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.85% | -3.92% | -4.85% | -10.09% | +77.11% | +53.13% | +66.10% | +13.08% | -45.66% | -88.33% | -69.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-12.3% Q1'26: -21.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+126.4% ★ Q1'26: +80.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-27.4% Q1'26: -10.9% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-28.7% Q1'26: -46.9% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-2.1% Q1'26: -3.4% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.57× Q1'26: -0.65× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 3 Rev. Ana. 2 EPS Ana. |
Mar 2027 1 Rev. Ana. 3 EPS Ana. |
Mar 2028 3 Rev. Ana. 3 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
631.28M
est: 743.33M (-15.1%)
|
1.26B
est: 1.16B (+8.7%)
|
1.66B
est: 1.74B (-4.7%)
|
1.73B
est: 2.17B (-20.4%)
|
1.71B
est: 1.89B (-9.6%)
|
1.79B
est: 1.72B (+4.2%)
|
1.88B
est: 1.86B (+0.9%)
|
2.15B
est: 2.15B (+0.0%)
|
3.29B
est: 3.23B (+2.0%)
|
4.35B
est: 4.46B (-2.5%)
|
4.38B
est: 4.44B (-1.3%)
|
4.13B
3.90B – 4.27B
-7.0% YoY
|
4.92B
4.61B – 5.48B
+19.0% YoY
|
5.85B
5.20B – 7.08B
+19.0% YoY
|
7.36B
6.91B – 8.21B
+25.9% YoY
|
10.83B
10.17B – 12.08B
+47.1% YoY
|
| EBITDA |
-1.56B
est: 118.68M (-1,417.7%)
|
-1.01B
est: 185.85M (-644.4%)
|
-854.00M
est: 278.04M (-407.2%)
|
-619.00M
est: 346.47M (-278.7%)
|
-789.00M
est: 301.76M (-361.5%)
|
-667.00M
est: 274.62M (-342.9%)
|
-413.00M
est: 296.77M (-239.2%)
|
-565.00M
est: 343.27M (-264.6%)
|
-722.00M
est: 514.91M (-240.2%)
|
-1.06B
est: -2.51M (-42,056.5%)
|
-904.00M
est: -2.50M (-36,080.8%)
|
-2.32M
-2.40M – -2.19M
+7.0% YoY
|
-2.77M
-3.09M – -2.60M
-19.0% YoY
|
-3.29M
-3.98M – -2.93M
-19.0% YoY
|
-4.14M
-4.62M – -3.89M
-25.9% YoY
|
-6.09M
-6.80M – -5.72M
-47.1% YoY
|
| EBIT |
-1.77B
est: -22.89M (-7,615.4%)
|
-1.29B
est: -35.84M (-3,504.8%)
|
-1.19B
est: -53.63M (-2,117.2%)
|
-1.02B
est: -66.82M (-1,423.4%)
|
-1.23B
est: -58.20M (-2,004.7%)
|
-1.16B
est: -52.97M (-2,088.2%)
|
-876.00M
est: -57.24M (-1,430.4%)
|
-1.05B
est: -66.21M (-1,481.4%)
|
-1.35B
est: -99.31M (-1,258.3%)
|
-1.74B
est: -381.97M (-354.5%)
|
-1.50B
est: -379.92M (-293.8%)
|
-353.39M
-365.37M – -333.71M
+7.0% YoY
|
-420.56M
-469.09M – -394.87M
-19.0% YoY
|
-500.51M
-605.47M – -444.95M
-19.0% YoY
|
-629.90M
-702.59M – -591.42M
-25.9% YoY
|
-926.52M
-1.03B – -869.92M
-47.1% YoY
|
| Net Income |
-915.89M
est: -710.81M (-28.9%)
|
-718.06M
est: -740.57M (+3.0%)
|
-676.00M
est: -657.82M (-2.8%)
|
-673.00M
est: -433.35M (-55.3%)
|
-632.00M
est: -343.52M (-84.0%)
|
-152.00M
est: -21.11M (-619.9%)
|
-59.00M
est: 127.50M (-146.3%)
|
-498.00M
est: -605.90M (+17.8%)
|
-298.00M
est: -186.15M (-60.1%)
|
-1.48B
est: -1.80B (+17.8%)
|
-577.00M
est: -531.89M (-8.5%)
|
141.50M
110.84M – 142.51M
+126.6% YoY
|
181.50M
-570.05M – 717.85M
+28.3% YoY
|
531.00M
-147.79M – 1.12B
+192.6% YoY
|
1.15B
696.73M – 1.60B
+116.6% YoY
|
2.20B
2.02B – 2.53B
+90.9% YoY
|
| SGA |
981.48M
est: 493.62M (+98.8%)
|
1.05B
est: 772.97M (+36.1%)
|
1.01B
est: 1.16B (-12.7%)
|
994.00M
est: 1.44B (-31.0%)
|
1.02B
est: 1.26B (-18.6%)
|
1.10B
est: 1.14B (-4.0%)
|
1.20B
est: 1.23B (-3.1%)
|
1.48B
est: 1.43B (+3.8%)
|
2.00B
est: 2.14B (-6.8%)
|
2.82B
est: 2.78B (+1.5%)
|
2.43B
est: 2.77B (-12.1%)
|
2.57B
2.43B – 2.66B
-7.0% YoY
|
3.06B
2.87B – 3.41B
+19.0% YoY
|
3.64B
3.24B – 4.41B
+19.0% YoY
|
4.59B
4.31B – 5.11B
+25.9% YoY
|
6.74B
6.33B – 7.52B
+47.1% YoY
|
| EPS |
-4.74
est: -3.37 (-40.8%)
|
-3.53
est: -3.51 (-0.6%)
|
-3.16
est: -3.12 (-1.4%)
|
-3.13
est: -2.05 (-52.5%)
|
-2.94
est: -1.63 (-80.7%)
|
-0.71
est: -0.10 (-610.0%)
|
-0.27
est: 0.60 (-144.7%)
|
-2.31
est: -2.87 (+19.5%)
|
-1.39
est: -0.85 (-63.5%)
|
-6.99
est: -8.50 (+17.8%)
|
-2.73
est: -2.43 (-12.2%)
|
0.60
0.53 – 0.68
+124.7% YoY
|
1.03
-2.70 – 3.40
+72.2% YoY
|
2.43
-0.70 – 5.30
+135.5% YoY
|
5.45
3.30 – 7.60
+124.0% YoY
|
10.40
9.57 – 11.96
+90.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P International Small Cap ETF GWX | 0.01% | 114.2K | 0.40% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shinji Honda | Executive Director & Chief Operating Officer | — | male |
| Yoshiyuki Sankai | Chairman, President & Chief Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7779.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
